Navigation Links
Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
Date:6/7/2008

le with type 2 diabetes who are unsuccessful at controlling their blood sugar levels. BYETTA is an add-on therapy for people currently using metformin, a sulfonylurea, or a thiazolidinedione. BYETTA provides sustained A1C control, low incidence of hypoglycemia when used with metformin or a thiazolidinedione, and progressive weight loss. BYETTA was approved in April 2005 and has been used by approximately one million patients since its introduction. For full prescribing information, visit http://www.BYETTA.com.

About Diabetes

Diabetes affects more than 21 million in the United States and an estimated 246 million adults worldwide.(1,2) Approximately 90-95 percent of those affected have type 2 diabetes. Diabetes is the fifth leading cause of death by disease in the United States and costs approximately $132 billion per year in direct and indirect medical expenses.(3)

According to the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve their target blood sugar levels with their current treatment regimen.(4) In addition, 85 percent of type 2 diabetes patients are overweight and 55 percent are considered obese.(5) Data support that weight loss (even a modest amount) supports patients in their efforts to achieve and sustain glycemic control.(6,7)

Important Safety Information for BYETTA

BYETTA improves glucose (blood sugar) control in adults with type 2 diabetes. It is used with metformin, a sulfonylurea, or a thiazolidinedione. BYETTA is not a substitute for insulin in patients whose diabetes requires insulin treatment. BYETTA is not recommended for use in patients with severe problems digesting food or those who have severe disease of the stomach or kidney.

When BYETTA is used with a medicine that contains a sulfonylurea, hypoglycemia (low blood sugar) is a possible side effec
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
2. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
3. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
4. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
5. New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data
6. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
7. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
8. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
9. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
10. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
11. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... PHILADELPHIA , Dec. 23, 2014 ... a medical device company focused on skin permeation, ... that Scott W. Hollander has been ... Mr. Hollander has more than 20 years of ... equipment industries, and most recently served as Vice ...
(Date:12/24/2014)... 23, 2014 ResMed (NYSE: RMD ) ... against Chinese medical device manufacturer BMC Medical Co., Ltd. ... BMC,s masks listed below infringe ResMed,s patents, and entered an ... in the United States : ... , Willow nasal pillows mask , iVolve full ...
(Date:12/24/2014)... 2014   Synageva BioPharma Corp. (NASDAQ: ... therapeutic products for rare disorders, today announced validation ... Marketing Authorization Application (MAA) for sebelipase alfa for ... request for accelerated assessment, which has the potential ... The MAA, and the Biologics License ...
Breaking Medicine Technology:Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
... from Mayo ClinicROCHESTER, Minn., March 23 Here ... Edge, Mayo Clinic,s research magazine. You may cite ... you wish. Reprinting is allowed with proper attribution. ... editorial policies permit: Visit http://discoverysedge.mayo.edu for ...
... Since 1993, when the PLCO trial was started, we have ... have others. The initial report of the results of this ... published last week in the New England Journal of Medicine ... The studies offer conflicting evidence about the possibility of a ...
Cached Medicine Technology:Discovery's Edge Spring Issue - http://discoverysedge.mayo.edu 2A Joint Statement From America's Prostate Cancer Advocacy, Education, and Support Organizations 2A Joint Statement From America's Prostate Cancer Advocacy, Education, and Support Organizations 3
(Date:12/25/2014)... “Every three months the trends for ... evening dress will be one of the hottest styles in ... says. Today, the company releases 26 A-line sweetheart evening dresses, ... off. , “We are trying our best to help ... latest designs. Along with affordable prices, we provide discounted delivery ...
(Date:12/25/2014)... Los Angeles, CA (PRWEB) December 25, 2014 ... Blaise Dolcemaschio was created in honor of a true ... premiere at two film festivals including the 24 hours of ... Film Festival in Bangladesh. , Actress, screenwriter and ... and helped produce this film together with her husband, ...
(Date:12/25/2014)... Helen Harris’ RP (Retinitis Pigmentosa) International founder ... an 8 year battle with breast cancer. , ... her home in Woodland Hills California after an 8 ... , As the founder and volunteer President of ... championed many of today's greatest breakthroughs in restoring and ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... children with complex chronic illnesses can receive effective, less expensive ... with easy access to a team of dedicated health care ... to become seriously ill and need either hospitalization or a ... an enhanced medical home clinic at the University of Texas ...
(Date:12/25/2014)... -- Among early stage breast cancer patients who undergo ... percent will eventually develop leukemia as a result of ... comes from a review of more than 20,000 breast ... suggests that the risk for developing treatment-related leukemia, though ... "The frequency of bone marrow cancers such as ...
Breaking Medicine News(10 mins):Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... CST-Arwin will represent the complete AC and DC line of axial ... more than 100 axial fans ranging in size from 25mm to ... ... -- NMB Technologies Corporation, a Minebea Group Company, and CST-Arwin, a ...
... WASHINGTON, DC, November 3, 2008 Parents are surprisingly ... visit to their child,s pediatrician, including those who have ... would look to their pediatrician for a referral, according ... the journal Pediatrics . , "This is a ...
... 3, 2008) Influenza vaccination rates for adolescents who suffer ... low, according to a recent study. , ... Pediatrics, was based at the Department of ... Harvard Pilgrim Health Care. , "Influenza vaccination has been ...
... RAMSEY, N.J., Nov. 3 Konica Minolta ... the industrial measurement of color,light and shape, ... Analysis Software.,This new software product used in ... accurate measurement of skin,color simultaneously with a ...
... two-pronged attack, a novel designer molecule fights malignant melanoma. It ... led by the University of Bonn. On the one hand, ... this way alerts the immune system. The body,s own defences ... the same time, the novel molecule also puts pressure on ...
... to Ask Voters ... of Health Care, TRENTON, N.J., Nov. 1 Calling themselves ... forces to ask the state,s public policy makers to put health ... level. The First Ladies,joined the newest members of the Partnership to ...
Cached Medicine News:Health News:NMB's Fans and Blowers to be Represented in Canada by CST-Arwin 2Health News:Parents comfortable with alcohol screening in pediatricians' offices 2Health News:Parents comfortable with alcohol screening in pediatricians' offices 3Health News:Flu vaccination rates lag for at-risk adolescents 2Health News:Konica Minolta Sensing Americas Announces the Launch of the CM-SA Skin Analysis Software 2Health News:Substance tackles skin cancer from 2 sides 2Health News:On Weekend Before the Election, New Jersey's First Ladies Speak Out for Healthcare 2Health News:On Weekend Before the Election, New Jersey's First Ladies Speak Out for Healthcare 3
Microalbumin Linearity Control...
Total IgE Control...
The K-ASSAY Lipid Controls are assayed controls produced from fresh human sera to monitor the accuracy and precision of quantitative lipid determinations of human sera specimens....
The K-ASSAY hs-CRP Control Set is intended to be used as a consistent test sample of known concentrations for monitoring the performance of hs-CRP (high sensitive C-Reactive Protein) immunoturbimetri...
Medicine Products: